News & Commentary

09.08.21 | Firms News

Dr. Craig Gordon Launches Alternative Investment Firm GordonMD Global Investments

Today Craig Gordon, MD, a licensed physician with over a decade of buy-side experience managing global biopharmaceutical portfolios, proudly announces the launch of GordonMD Global Investments.

09.08.21

Dr. Craig Gordon Launches Alternative Investment Firm GordonMD Global Investments

Today Craig Gordon, MD, a licensed physician with over a decade of buy-side experience managing global biopharmaceutical portfolios, proudly announces the launch of GordonMD Global Investments.

03.22.22

Spotlight Therapeutics Raises $36.5 Million Series B to Advance a Pipeline of Cell-Targeted In Vivo CRISPR Gene Editing Biologics

Spotlight Therapeutics, Inc. (“Spotlight”), a biotechnology company applying new insights to develop cell-targeted in vivo CRISPR gene editing biologics, today announced a $36.5M Series B financing to fuel a drive toward the clinic.

01.05.22

SalioGen Therapeutics Closes $115 Million Oversubscribed Series B Financing to Advance Gene CodingTM – A New Category of Genetic Medicine

SalioGen Therapeutics, a privately held biotechnology company developing Gene CodingTM, a new category of genetic medicine, today announced the completion of an oversubscribed and up-sized $115 million Series B financing.

11.03.21

Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV

We are excited to announce the completion of our Series B-1 financing, a $75 million raise co-led by GordonMD Global Investments and the EPIQ Capital Group.

Market Commentary are coming soon.